Literature DB >> 2398458

Hyponatremia in patients with acquired immune deficiency syndrome.

A J Cusano1, H L Thies, F P Siegal, A W Dreisbach, J K Maesaka.   

Abstract

We performed prospective and retrospective studies of 96 consecutive patients with acquired immune deficiency syndrome (AIDS) or AIDS-related complex (ARC) to determine the incidence, pathogenesis, and clinical significance of hyponatremia, defined as serum sodium levels less than or equal to 130 mmol/L on more than one occasion. Thirty (31.3%), six with ARC and 24 with AIDS, had hyponatremia, and it developed in 20 as outpatients. Age, gender, duration of illness, and weight loss did not differ between groups. The hyponatremic patient had more opportunistic illnesses, including Pneumocystis carinii pneumonia and cytomegalovirus infections, and had a mortality of 70% as compared to 36.4% of the patients without hyponatremia. The probability of 50% survival after diagnosis of human immunodeficiency virus (HIV) infection in the hyponatremic group was 11.5 months, as compared to 39 months for those without hyponatremia, p less than 0.001. The probability of 50% survival after development of hyponatremia was 4.5 months and the median length of time to development of hyponatremia was 12.5 months after diagnosis of HIV infection. Eighty-eight percent had hypovolemia and 12% normovolemia. Seventeen of 21 with hypovolemia had no evident source of fluid loss. Two had Addison's disease, and 15 had unexpectedly high urine sodium concentration without evidence of renal or adrenal insufficiency. Hyponatremia occurs commonly in ambulatory patients with ARC or AIDS, appears in patients with higher mortality and morbidity, and does not represent a terminal event. Most patients had hypovolemia and unexpectedly high urine sodium concentration, suggesting defective renal sodium conservation.

Entities:  

Mesh:

Year:  1990        PMID: 2398458

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  16 in total

1.  Cytomegalovirus adrenalitis in acquired immunodeficiency syndrome.

Authors:  Brian Chiu; Jack Butany; Kaiman Kovacs; Zi Cheng
Journal:  Endocr Pathol       Date:  1994-12       Impact factor: 3.943

Review 2.  HIV-associated renal disorders: recent insights into pathogenesis and treatment.

Authors:  Ruth Berggren; Vecihi Batuman
Journal:  Curr HIV/AIDS Rep       Date:  2005-08       Impact factor: 5.071

Review 3.  Management of hyponatraemia.

Authors:  A I Arieff
Journal:  BMJ       Date:  1993-07-31

Review 4.  Electrolyte and acid-base disorders associated with AIDS: an etiologic review.

Authors:  M A Perazella; E Brown
Journal:  J Gen Intern Med       Date:  1994-04       Impact factor: 5.128

Review 5.  Water, electrolytes, and acid-base alterations in human immunodeficiency virus infected patients.

Authors:  Carlos G Musso; Waldo H Belloso; Richard J Glassock
Journal:  World J Nephrol       Date:  2016-01-06

6.  Renal disease in patients with HIV.

Authors:  Christina M Wyatt; Jonathan Winston
Journal:  Curr Infect Dis Rep       Date:  2006-01       Impact factor: 3.725

7.  More on renal salt wasting without cerebral disease: response to saline infusion.

Authors:  Solomon Bitew; Louis Imbriano; Nobuyuki Miyawaki; Steven Fishbane; John K Maesaka
Journal:  Clin J Am Soc Nephrol       Date:  2009-02       Impact factor: 8.237

8.  Adrenocortical function in Nigerians with human immunodeficiency virus infection.

Authors:  I A Odeniyi; O A Fasanmade; M O Ajala; A E Ohwovoriole
Journal:  Ghana Med J       Date:  2013-12

Review 9.  Principles of management of severe hyponatremia.

Authors:  Antonios H Tzamaloukas; Deepak Malhotra; Bradley H Rosen; Dominic S C Raj; Glen H Murata; Joseph I Shapiro
Journal:  J Am Heart Assoc       Date:  2013-01-23       Impact factor: 5.501

10.  Moderate hyponatremia is associated with increased risk of mortality: evidence from a meta-analysis.

Authors:  Giovanni Corona; Corinna Giuliani; Gabriele Parenti; Dario Norello; Joseph G Verbalis; Gianni Forti; Mario Maggi; Alessandro Peri
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.